

AML Hub | Quarter One 2020 Update

Thursday 2 April, 2020

The [AML Hub](#) continues to be a reputable, unbiased source of the latest clinical updates and advances in acute myeloid leukemia (AML) for healthcare professionals, worldwide.

Guided by an executive steering committee and scientific advisory board of world-leading experts in AML, the AML Hub, in association with the [European LeukemiaNet](#) (ELN), act to disseminate the latest clinical updates in AML, ensuring healthcare teams are informed and patients with AML have access to the latest drugs and clinical trials. Sadly, March saw the [passing](#) of Executive Steering Committee Honorary Chair, Clara D. Bloomfield, who passed away aged 77 on March 2, 2020.

During Q1, the AML Global Portal rebranded to the AML Hub, in line with our sister hubs, [Lymphoma Hub](#), [Multiple Myeloma Hub](#), and [GvHD Hub](#). All links to existing content will be automatically redirected to the new webpage and remain freely accessible.

Last quarter, the AML Hub physically attended the [2nd European CAR T meeting](#), Sitges, ES, and virtually covered the [Transplantation & Cellular Therapy Meetings](#) of ASTCT and CIBMTR. During the CAR-T meeting, the AML Hub conducted interviews with world-leading experts and produced written content. During the TCT meeting, the AML Hub disseminated slides from key sessions via social media and are producing written articles from prominent sessions. The AML Hub was recognized as a top influencer at both meetings, based on the comprehensive live social media coverage provided.

The first AML Hub [Satellite Symposium](#), planned for March 22, 2020, during the [46th European Society of Blood and Marrow Transplantation](#) (EBMT) meeting, has been rescheduled to August 30, 2020, in line with the new dates of the EBMT meeting. During the symposium, five international experts — Gert Ossenkoppele, Jacqueline Cloos, Christian Thiede, Adriano Venditti, and Charles Craddock — will discuss the latest developments and remaining challenges of minimal residual disease assessments in the context of stem cell transplant outcomes.

During the first part of Q1, the AML Hub focused on generating content from the 61st [American Society of Hematology](#) (ASH) meeting, including [practice changing abstracts](#) with comments from our world-leading experts. Following this, the AML Hub has continued to champion editorial themes, such as [novel combination therapies using targeted agents](#).

The AML Hub is a platform delivered by [Scientific Education Support](#) (SES), who strive to bring increased knowledge and awareness to healthcare professionals via collaborative networks across the globe.

The AML Hub would like to welcome [Astellas](#) as a new bronze supporter and thank our silver supporters, [Amgen](#), [AbbVie](#), [Roche](#), [Genentech](#), [Daiichi-Sankyo](#), and [Novartis](#); bronze supporters, [Celgene](#), [Janssen Oncology](#), [Jazz Pharmaceuticals](#), and [Pfizer](#); and contributors, [Agiros](#) and [Helsinn](#), for their continued support of the initiative.

For more information on the AML Hub, please visit <https://aml-hub.com/>

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com

Related Sectors:

Health :: Media & Marketing ::
Medical & Pharmaceutical ::

Related Keywords:

AML :: Acute Myeloid Leukemia
:: Cancer :: Hematology ::

Scan Me:



Company Contact:

Scientific Education Support

E. [Abbie.Gunn@scientificeducationsupport...](mailto:Abbie.Gunn@scientificeducationsupport.co.uk)

W. [https://www.scientificeducationsuppor...](https://www.scientificeducationsupport.co.uk)

View Online

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.scientific-education-support.pressat.co.uk>